Literature DB >> 29281097

Decision Making in the Wait-and-Scan Approach for Vestibular Schwannomas: Is There a Price to Pay in Terms of Hearing, Facial Nerve, and Overall Outcomes?

Sampath Chandra Prasad1, Uma Patnaik1,2, Golda Grinblat1, Annalisa Giannuzzi1, Enrico Piccirillo1, Abdelkader Taibah1, Mario Sanna1.   

Abstract

BACKGROUND: The wait-and-scan modality has emerged as an important strategy in the management of vestibular schwannoma (VS) as it has been demonstrated that many tumors grow slowly or do not show any growth over long periods.
OBJECTIVE: To analyze long-term outcomes of wait-and-scan in the treatment of patients with VS, discuss the factors contributing to the decision making, determine the inherent risks of the policy, and compare our results with literature.
METHODS: In total, 576 patients with sporadic unilateral VS who were managed with wait-and-scan were reviewed retrospectively. Of these, a subset of 154 patients with 5-yr follow-up was separately analyzed. The tumor characteristics including patterns of growth, rate of growth, hearing outcomes, and likely factors affecting the above parameters were analyzed.
RESULTS: The mean period of follow-up was 36.9 ± 30.2 mo. The mean age was 59.2 ± 11.6 yr. Thirteen different patterns of tumor growth were observed. Eighty-four (54.5%) of 154 tumors with 5-yr follow-up showed no growth throughout 5 yr. Fifty-six (36.4%) tumors showed mixed growth rates. Only 57 (37%) patients had serviceable hearing at the start of follow-up, but 32 (56.1%) maintained it at the end of follow-up. One hundred fifty (26%) of the 576 patients who failed wait-and-scan had to be taken up for surgery.
CONCLUSION: While there may be no price to pay in wait-and-scan as far as hearing is concerned, this may not be the case for facial nerve outcomes, wherein the results may be better if the patients are taken earlier for surgery.

Entities:  

Mesh:

Year:  2018        PMID: 29281097     DOI: 10.1093/neuros/nyx568

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  Facial Nerve Function After Microsurgical Resection in Vestibular Schwannoma Under Neurophysiological Monitoring.

Authors:  Felix Arlt; Johannes Kasper; Dirk Winkler; Katja Jähne; Michael Karl Fehrenbach; Jürgen Meixensberger; Caroline Sander
Journal:  Front Neurol       Date:  2022-05-24       Impact factor: 4.086

2.  Cochleo-facial corridor to the vestibule and fundus of the internal auditory canal through oval window: a minimal invasive and cochlea sparing approach.

Authors:  Derya Ümit Talas; Orhan Beger; Yusuf Vayisoğlu; Vural Hamzaoğlu; Hakan Özalp; Salim Çakır; Ahmet Dağtekin; Celal Bağdatoğlu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-17       Impact factor: 2.503

3.  Reduced grey- and white matter volumes due to unilateral hearing loss following treatment for vestibular schwannoma.

Authors:  Peder O Laugen Heggdal; Kristina S Larsen; Jonas Brännström; Hans Jørgen Aarstad; Karsten Specht
Journal:  Heliyon       Date:  2020-12-17

Review 4.  Shared decision-making in neurosurgery: a scoping review.

Authors:  Alba Corell; Annie Guo; Tomás Gómez Vecchio; Anneli Ozanne; Asgeir S Jakola
Journal:  Acta Neurochir (Wien)       Date:  2021-05-03       Impact factor: 2.216

5.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

6.  Initial Observation among Patients with Vestibular Schwannoma.

Authors:  Henry Ruiz-Garcia; Jennifer Peterson; Janet Leon; Timothy Malouff; Laura Vallow; Larry Lundy; Kaisorn L Chaichana; Prasanna Vibhute; Daniel M Trifiletti
Journal:  J Neurol Surg B Skull Base       Date:  2020-01-24

7.  Decision making on vestibular schwannoma treatment: predictions based on machine-learning analysis.

Authors:  Oliver Profant; Zbyněk Bureš; Zuzana Balogová; Jan Betka; Zdeněk Fík; Martin Chovanec; Jan Voráček
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.